Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Current Liabilities (2017 - 2025)

Aclaris Therapeutics has reported Total Current Liabilities over the past 9 years, most recently at $28.6 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $28.6 million for Q4 2025, down 9.34% from a year ago — trailing twelve months through Dec 2025 was $28.6 million (down 9.34% YoY), and the annual figure for FY2025 was $28.6 million, down 9.34%.
  • Total Current Liabilities for Q4 2025 was $28.6 million at Aclaris Therapeutics, up from $25.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for ACRS hit a ceiling of $31.6 million in Q4 2024 and a floor of $14.5 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $20.8 million (2024), compared with a mean of $21.7 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 31.31% in 2024 and later surged 71.15% in 2025.
  • Aclaris Therapeutics' Total Current Liabilities stood at $22.9 million in 2021, then fell by 4.33% to $21.9 million in 2022, then surged by 41.09% to $31.0 million in 2023, then grew by 2.08% to $31.6 million in 2024, then dropped by 9.34% to $28.6 million in 2025.
  • The last three reported values for Total Current Liabilities were $28.6 million (Q4 2025), $25.6 million (Q3 2025), and $26.8 million (Q2 2025) per Business Quant data.